Vandetanib: An overview of its clinical development in NSCLC and other tumors

Drugs of Today

Volumn 46, Issue 9, 2010, Pages 683-698

  Morabito, Alessandro ^a   Piccirillo, M C ^b   Costanzo, R ^a   Sandomenico, C ^a   Carillio, G ^c   Daniele, G ^b   Giordano, P ^b   Bryce, J ^b   Carotenuto, P ^d   La Rocca, A ^b   Di Maio, M ^b   Normanno, N ^b,d   Rocco, G ^b   Perrone, F ^b  

^a National Cancer Institute   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c PUGLIESE CIACCIO HOSPITAL   (Italy)

^d Centro di Ricerche Oncologiche di Mercogliano CROM   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BORTEZOMIB; CALCITONIN; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CYTOKINE; DOCETAXEL; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; FULVESTRANT; GEFITINIB; GELATINASE B; GEMCITABINE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 12; INTERLEUKIN 8; IRINOTECAN; MONOCYTE CHEMOTACTIC PROTEIN 1; OXALIPLATIN; PACLITAXEL; PEMETREXED; PREDNISOLONE; TAXANE DERIVATIVE; UNINDEXED DRUG; VANDETANIB;

ACNE; ADENOCARCINOMA; ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BLOODY DIARRHEA; BRAIN METASTASIS; BREAST CANCER; CALCITONIN BLOOD LEVEL; CANCER GROWTH; CANCER RADIOTHERAPY; COLORECTAL CANCER; CREATININE BLOOD LEVEL; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE CONTROL; DIZZINESS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; ENZYME PHOSPHORYLATION; FATIGUE; GENE MUTATION; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; HYPERTENSION; LIVER CELL CARCINOMA; LOW DRUG DOSE; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; LYMPHOMA; MAINTENANCE THERAPY; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; PRURITUS; QT PROLONGATION; RACE; RADIOSENSITIVITY; RADIOTHERAPY; RECOMMENDED DRUG DOSE; RECURRENT CANCER; REVIEW; SENSORY NEUROPATHY; SEX DIFFERENCE; SIDE EFFECT; SMOKING; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA; THYROID CANCER; TREATMENT OUTCOME; TUMOR GROWTH; UREA NITROGEN BLOOD LEVEL; URINARY TRACT CANCER;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; NEOPLASMS; PIPERIDINES; QUINAZOLINES;

EID: 79955891953     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.9.1516989     Document Type: Review

References (59)

1. Hennequin, L.F., Stokes, E.S., Thomas, A.P. et al. Novel 4-anlllnoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase Inhibitors. J Med Chem 2002, 45(6): 1300-12. (Pubitemid 34263566)
2. Carlomagno, F., Vitagliano, D., Guida, T. et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002, 62(24): 7284-90. (Pubitemid 36025251)
3. Ciardiello, F., Caputo, R., Damiano, V. et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003, 9(4): 1546-56. (Pubitemid 36418413)
4. Ferrara, N. Molecular and biological properties of vascular endothelial growth factor. J Mol Med 1999, 77(7): 527-43.
5. Gille, H., Kowalski, J., Li, B. et al. Analysis of biological effects and signalling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). J Biol Chem 2001, 276(5): 3222-30.
6. Wells, A. EGF receptors. Int J Biochem Cell Biol 1999, 31(6): 637-43.
7. De Luca, A., Carotenuto, A., Rachiglio, A. et al. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 2008, 214(3): 559-67. (Pubitemid 351224199)
8. Lodish, M.B., Stratakis, C.A. RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer. Expert Rev Anticancer Ther 2008, 8(4): 625-32. (Pubitemid 351818356)
9. Tonra, J.R., Deevi, D.S., Corcoran, E., Li, H., Wang, S., Carrick, F.E., Hicklin, D.J. Synergistic antitumor effects of combined epidermal growth factor receptor and vascular endothelial growth factor receptor-2 targeted therapy. Clin Cancer Res 2006, 12(7, Pt. 1): 2197-207.
10. Wedge, S.R., Ogilvie, D.J., Dukes, M. et al. ZD6474 inhibits vascular endothelial growth factor signaling, anglogenesis, and tumor growth following oral administration. Cancer Res 2002, 62(16): 4645-55.
11. Wu, W., Onn, A., Isobe, T. et al. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 2007, 6(2): 471-83. (Pubitemid 46332449)
12. McCarty, M.F., Wey, J., Stoeltzing, O. et al. ZD6474 a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and anglogenesis of gastric cancer. Mol Cancer Ther 2004, 3(9): 1042-8.
13. Conrad, C., Ischenko, I., Köhl, G. et al. Anti-angiogenic and antitumor activity of a novel VEGFR-2 tyrosine kinase activity inhibitor ZD6474 in a metastatic human pancreatic tumor model. Anticancer Drugs 2007, 18(5): 569-79. (Pubitemid 46597412)
14. Drevs, J., Konerding, M.A., Wolloscheck, T. et al. The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvasculature architecture within an orthotopically implanted renal cell carcinoma. Angiogenesis 2004, 7(4): 347-54. (Pubitemid 40767936)
15. Checkley, D., Tessier, J.J., Kendrew, J. et al. Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumors. Br J Cancer 2003, 89(10): 1889-95. (Pubitemid 37533265)
16. Bradley, D.P., Tessier, J.T., Checkley, D. et al. The VEGF signaling inhibitors ZD6474 and AZD2171 compromise hemodynamic parameters in an SW620 human colon tumor model: An analysis using perfusion-permeability dynamic contrast-enhanced magnetic resonance imaging (pp-DCE-MRI). Proc Amer Assoc Cancer Res 2004, 45: Abst 4552.
17. Ciardiello, F., Bianco, R., Caputo, R. et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004, 10(2): 784-93. (Pubitemid 38174017)
18. Taguchi, F., Koh, Y., Koizumi, F., Tamura, T., Saijo, N., Nishio, K. Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib-sensitive and -resistant xenograft models. Cancer Sci 2004, 95(12): 984-9. (Pubitemid 40089591)
19. Troiani, T., Lockerbie, O., Morrow, M. et al. Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases. Mol Cancer Ther. 2006, 5(7): 1883-94. (Pubitemid 44323257)
20. Hoang, T., Huang, S.M., Armstrong, E.A. et al. Augmentation of radiation response with the VEGFR-tyrosine kinase inhibitor ZD6474. Proc Am Assoc Cancer Res 2004, 45: Abst 955.
21. Williams, K.J., Telfer, B.A., Brave, S. et al. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule dependent enhancement of antitumor activity. Clin Cancer Res 2004, 10(24): 8587-93. (Pubitemid 40053426)
22. Bianco, C., Giovannetti, E., Ciardiello, F. et al. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. Clin Cancer Res 2006, 12(23): 7099-107.
23. Holden, S.N., Eckhardt, S.G., Basser, R. et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005, 16(8): 1391-7. (Pubitemid 41158486)
24. Tamura, T., Minami, H., Yamada, Y. et al. A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors. J Thorac Oncol 2006, 1(9): 1002-9. (Pubitemid 47181370)
25. De Boer, R., Humblet, Y., Wolf, J. et al. An open-label study of vandetanib with pemetrexed in patients with previously treated non-small cell lung cancer. Ann Oncol 2009, 20(3): 486-91.
26. Saunders, M.P., Wilson, R., Peeters, M., Smith, R., Godwood, A., Oliver, S., Van Cutsem, E. Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: Results from an open-label, multicentre phase I study. Cancer Chemother Pharmacol 2009, 64(4): 665-72.
27. Michael, M., Gibbs, P., Smith, R., Godwood, A., Oliver, S., Tebbutt, N. Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer. Invest New Drugs 2009, 27(3): 253-61.
28. Morabito, A., Piccirillo, M.C., Falasconi, F. et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: Current status and future directions. Oncologist 2009, 14(4): 378-90.
29. Heymach, J.V., Johnson, B.E., Prager, D. et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small cell lung cancer. J Clin Oncol 2007, 25(27): 4270-7. (Pubitemid 47548567)
30. Heymach, J.V., Paz-Ares, L., De Braud, F. et al. Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2008, 26(33): 5407-15.
31. Kiura, K., Nakagawa, K., Shinkai, T. et al. A randomized double-blind phase IIa dose-finding study of ZD6474 in Japanese patients with NSCLC. J Thorac Oncol 2008, 3(4): 386-93. (Pubitemid 351489479)
32. Natale, R.B., Bodkin, D., Govindan, R. et al. Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: Results from a two-part, double-blind, randomized phase II study. J Clin Oncol 2009, 27(15): 2523-9.
33. Hanrahan, E.O., Lin, H.Y., Kim, E.S. et al. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2010, 28(2): 193-201.
34. Hanrahan, E.O., Ryan, A.J., Mann, H. et al. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 2009, 15(10): 3600-9.
35. Natale, R.B., Thongprasert, S., Greco, F.A. et al. Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST). J Clin Oncol 2009, 27(15, Suppl.): Abst 8009.
36. Lee, J., Hirsh, V., Park, K. et al. Vandetanib versus placebo in patients with advanced non-small cell lung cancer (NSCLC) after prior therapy with an EGFR tyrosine kinase inhibitor (TKI): A randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2010, 28(7, Suppl.): Abst 7525.
37. Herbst, R.S., Sun, Y., Eberhardt, W.E.E. et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small cell lung cancer (ZODIAC): A double-blind, randomized, phase 3 trial. Lancet Oncol 2010, 11(7): 619-26.
38. De Boer, R., Arrieta, O., Gottfried, M. et al. Vandetanib plus pemetrexed versus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer (NSCLC): A randomized, double-blind phase III trial (ZEAL). J Clin Oncol 2009, 27(15, Suppl.): Abst 8010.
39. Johnson, B.E., Ryan, A.J., Heymach, J.V. et al. Tumor biomarker analyses from the phase III ZODIAC study of docetaxel + vandetanib in 2nd-line advanced NSCLC. J Clin Oncol 2010, 28(7, Suppl.): Abst 7516.
40. Wells, S.A. Jr., Gosnell, J.E., Gagel, R.F. et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010, 28(5): 767-72.
41. Robinson, B.G., Paz-Ares, L., Krebs, A., Vasselli, J., Haddad, R. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010, 95(6): 2664-71.
42. Wells, S.A., Robinson, B.G., Gagel, R.F. et al. Vandetanib (VAN) in locally advanced or metastatic medullary thyroid cancer (MTC): A randomized, double-blind phase III trial (ZETA). J Clin Oncol 2010, 28(15, Suppl.): Abst 5503.
43. Miller, K.D., Trigo, J.M., Wheeler, C., Barge, A., Rowbottom, .J, Sledge, G., Baselga, J. A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer. Clin Cancer Res 2005, 11(9): 3369-76. (Pubitemid 40627889)
44. Boer, K., Lang, I., Llombart-Cussac, A., Andreasson, I., Vivanco, G.L., Sanders, N., Pover, G.M., Murray, E. Vandetanib with docetaxel as second line treatment for advanced breast cancer: A double-blind, placebo-controlled, randomized phase II study. San Antonio Breast Cancer Symposium (Dec 13-16, San Antonio) 2007, Abst 6081.
45. Arnold, A.M., Seymour, L., Smylie, M. et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. J Clin Oncol 2007, 25(27): 4278-84. (Pubitemid 47548568)
46. Annunziata, C.M., Walker, A.J., Minasian, L. et al. Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. Clin Cancer Res 2010, 16(2): 664-72.
47. Horti, J., Widmark, A., Stenzl, A. et al. A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer. Cancer Biother Radiopharm 2009, 24(2): 175-80.
48. Kovacs, M.J., Reece, D.E., Marcellus, D., Meyer, R.M., Mathews, S., Dong, R.P., Eisenhauer, E. A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma - NCIC CTG IND.145. Invest New Drugs 2006, 24(6): 529-35.
49. Yang, T.S., Oh, D.Y., Guimbaud, R. et al. Vandetanib plus mFOLFOX6 in patients with advanced colorectal cancer (CRC): A randomized, double-blind, placebo-controlled phase II study. J Clin Oncol 2009, 27(15, Suppl.): Abst 4084.
50. Mcnicol, K.A., Kreisl, T.N., Iwamoto, F.M., Sul, J., Fine, H.A. Phase I/II study of vandetanib for patients with recurrent malignant gliomas. J Clin Oncol 2010, 28(15, Suppl.): Abst 2083.
51. El-Khoueiry, A.B., Iqbal, S., Lenz, H. et al. A phase I study of two different schedules of nab-paclitaxel (Nab-p) with ascending doses of vandetanib (V) in patients (pts) with advanced solid tumors. J Clin Oncol 2010, 28(7, Suppl.): Abst 3059.
52. Gasparini, G., Longo, R., Torino, F. et al. Is tailored therapy feasible in oncology? Crit Rev Oncol Hematol 2006, 57(1): 79-101.
53. Gasparini, G., Longo, R., Fanelli, M. et al. Combination of antiangiogenic therapy with other anticancer therapies: Results, challenges, and open questions. J Clin Oncol 2005, 23(6): 1295-311. (Pubitemid 46202288)
54. Morabito, A., Di Maio, M., De Maio, E. et al. Methodology of clinical trials with new molecular-targeted agents: Where do we stand? Ann Oncol 2006, 17(Suppl. 7): vii128-31.
55. Morabito, A., De Maio, E., Di Maio, M., Normanno, N., Perrone, F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: Current status and future directions. The Oncologist 2006, 11(7): 753-64. (Pubitemid 44157563)
56. Di Maio, M., Gridelli, C., Normanno, N. et al. Trying to compose the puzzle with all the pieces: Epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. J Cell Physiol 2005, 205(3): 355-63. (Pubitemid 41598849)
57. Verheul, H.M.W., Pinedo, H.M. Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev 2007, 7(6): 475-85. (Pubitemid 46809172)
58. Haverkamp, W., Breithardt, G., Camm, A.J. et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications. Cardiovasc Res 2000, 47(2): 219-33.
59. Strevel, E.L., Ing, D.J., Siu, LL. Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 2007, 25(22): 3362-71. (Pubitemid 47325624)